Connection

GUILLERMINA LOZANO to Female

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Female.
Connection Strength

0.396
  1. Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. Proc Natl Acad Sci U S A. 2022 Nov 08; 119(45):e2210618119.
    View in: PubMed
    Score: 0.025
  2. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021 08; 11(8):2094-2111.
    View in: PubMed
    Score: 0.022
  3. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci U S A. 2020 09 22; 117(38):23663-23673.
    View in: PubMed
    Score: 0.021
  4. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6622-6629.
    View in: PubMed
    Score: 0.021
  5. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun. 2018 09 27; 9(1):3953.
    View in: PubMed
    Score: 0.019
  6. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 01 18; 37(3):332-340.
    View in: PubMed
    Score: 0.017
  7. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.017
  8. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene. 2016 11 03; 35(44):5713-5721.
    View in: PubMed
    Score: 0.016
  9. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
    View in: PubMed
    Score: 0.014
  10. Che-ating death: CHE1/AATF protects from p53-mediated apoptosis. EMBO J. 2012 Oct 17; 31(20):3951-3.
    View in: PubMed
    Score: 0.012
  11. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010 Sep 15; 70(18):7148-54.
    View in: PubMed
    Score: 0.011
  12. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene. 2008 Mar 20; 27(13):1813-20.
    View in: PubMed
    Score: 0.009
  13. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007 May; 18(5):300-9.
    View in: PubMed
    Score: 0.009
  14. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation. 2007 Jun 12; 115(23):2925-30.
    View in: PubMed
    Score: 0.009
  15. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 2007 Oct 18; 26(48):6896-904.
    View in: PubMed
    Score: 0.009
  16. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3226-31.
    View in: PubMed
    Score: 0.008
  17. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003 Dec 15; 63(24):8664-9.
    View in: PubMed
    Score: 0.007
  18. The histone chaperone function of Daxx is dispensable for embryonic development. Cell Death Dis. 2023 08 26; 14(8):565.
    View in: PubMed
    Score: 0.007
  19. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002 May 16; 21(22):3525-31.
    View in: PubMed
    Score: 0.006
  20. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021 11 19; 106(12):e4969-e4980.
    View in: PubMed
    Score: 0.006
  21. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021 09 10; 12(1):5389.
    View in: PubMed
    Score: 0.006
  22. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83.
    View in: PubMed
    Score: 0.006
  23. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35.
    View in: PubMed
    Score: 0.006
  24. The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Res. 2021 05 01; 81(9):2442-2456.
    View in: PubMed
    Score: 0.006
  25. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4174-9.
    View in: PubMed
    Score: 0.005
  26. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nat Commun. 2019 11 26; 10(1):5385.
    View in: PubMed
    Score: 0.005
  27. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8.
    View in: PubMed
    Score: 0.005
  28. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999 Mar; 10(3):147-54.
    View in: PubMed
    Score: 0.005
  29. Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proc Natl Acad Sci U S A. 2019 01 15; 116(3):960-969.
    View in: PubMed
    Score: 0.005
  30. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet. 1998 Jun; 102(6):681-6.
    View in: PubMed
    Score: 0.005
  31. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.004
  32. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 1997 Sep; 3(9):390-5.
    View in: PubMed
    Score: 0.004
  33. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res. 1997 Aug; 148(2):115-22.
    View in: PubMed
    Score: 0.004
  34. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016 09 08; 35(36):4798-806.
    View in: PubMed
    Score: 0.004
  35. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
    View in: PubMed
    Score: 0.004
  36. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 09; 378(6553):203-6.
    View in: PubMed
    Score: 0.004
  37. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19.
    View in: PubMed
    Score: 0.004
  38. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle. 2013 Jun 01; 12(11):1722-31.
    View in: PubMed
    Score: 0.003
  39. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov 01; 18(21 Suppl):S1-100.
    View in: PubMed
    Score: 0.003
  40. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-? (TGF-?). J Biol Chem. 2011 Dec 23; 286(51):44023-44034.
    View in: PubMed
    Score: 0.003
  41. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011 Jul 12; 20(1):79-91.
    View in: PubMed
    Score: 0.003
  42. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol. 2011 Sep; 42(9):1213-20.
    View in: PubMed
    Score: 0.003
  43. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
    View in: PubMed
    Score: 0.003
  44. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet. 2011 Jun; 129(6):663-73.
    View in: PubMed
    Score: 0.003
  45. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011 Mar; 121(3):851-65.
    View in: PubMed
    Score: 0.003
  46. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010 May 26; 5(5):e10813.
    View in: PubMed
    Score: 0.003
  47. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 2010 Jun 03; 29(22):3287-96.
    View in: PubMed
    Score: 0.003
  48. An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One. 2008 Apr 09; 3(4):e1951.
    View in: PubMed
    Score: 0.002
  49. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.002
  50. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice. Genes Chromosomes Cancer. 2006 Jul; 45(7):668-75.
    View in: PubMed
    Score: 0.002
  51. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 2005 Jan 15; 65(2):427-31.
    View in: PubMed
    Score: 0.002
  52. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.002
  53. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev. 2004 Aug; 13(8):1403-6.
    View in: PubMed
    Score: 0.002
  54. Novel p53 germline mutation in a patient with Li-Fraumeni syndrome. Intern Med J. 2003 Dec; 33(12):621.
    View in: PubMed
    Score: 0.002
  55. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol. 2003 Oct; 23(20):7096-107.
    View in: PubMed
    Score: 0.002
  56. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet. 2003 Aug; 113(3):238-43.
    View in: PubMed
    Score: 0.002
  57. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003 Apr; 72(4):975-83.
    View in: PubMed
    Score: 0.002
  58. TP53 mutation and haplotype analysis of two large African American families. Hum Mutat. 1999; 14(3):216-21.
    View in: PubMed
    Score: 0.001
  59. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 1998 Feb 15; 58(4):698-703.
    View in: PubMed
    Score: 0.001
  60. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997 Mar 15; 11(6):714-25.
    View in: PubMed
    Score: 0.001
  61. Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor beta 1-3 and their receptors in mouse jejunum after radiation treatment. Radiat Res. 1997 Jan; 147(1):1-12.
    View in: PubMed
    Score: 0.001
  62. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene. 1996 Sep 19; 13(6):1315-22.
    View in: PubMed
    Score: 0.001
  63. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest. 1995 Oct; 96(4):1874-86.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.